Cargando…
Genetic Background of Polycythemia Vera
Polycythemia vera belongs to myeloproliferative neoplasms, essentially by affecting the erythroblastic lineage. JAK2 alterations have emerged as major driver mutations triggering PV-phenotype with the V617F mutation detected in nearly 98% of cases. That’s why JAK2 targeting therapeutic strategies ha...
Autores principales: | Regimbeau, Mathilde, Mary, Romain, Hermetet, François, Girodon, François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027017/ https://www.ncbi.nlm.nih.gov/pubmed/35456443 http://dx.doi.org/10.3390/genes13040637 |
Ejemplares similares
-
Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms
por: De Almeida, Steven, et al.
Publicado: (2020) -
Diagnosis of exon 12‐positive polycythemia vera rescued by NGS
por: Geay, Antoine, et al.
Publicado: (2020) -
Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016) -
Thromboembolic events in polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2019) -
Polycythemia Vera: Thinking Beyond the Hematocrit
por: Waggoner, Matthew
Publicado: (2023)